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Summary
Patients on oral anticoagulant therapy (OAT) may bleed due to a
very low factor IX level caused by a mutation at Ala-10 in the
propeptide region of the factor IX gene. We evaluated screening of
patients on OAT with an APTT to detect patients with this abnormality.
In 734 patients an APTT was assessed. Twenty-three patients had a
disproportionately prolonged APTT. In these patients the factor IX
level, the mutation at Ala-10 and the frequency of bleeding complica-
tions were assessed. No severely lowered factor IX levels were found
(l patient with 5% factor IX). No mutations at Ala-10 were found and
bleeding complications were not raore frequent in these patients.
Concjusion: Routine APTT screening of patients on OAT is not useful
to detect patients with increased bleeding or with the Ala-10 mutation
in the factor IX gene.
Introduction
Oral anticoagulant therapy (OAT) with coumarin derivatives results
in defective synthesis of the vitamin K-dependent proteins. These
proteins include the procoagulant factors II, VII, IX and X and the
anticoagulant proteins C and S. In patients, oral anticoagulant therapy
is regulated on the results of the INR (international normalized ratio)
which is derived from the prothrombin time. The prothrombin time
measures the classical extrinsic pathway of blood coagulation which
includes the vitamin K-dependent factors II, VII and X and excludes
factor IX. Factor IX is involved in the intrinsic pathway of coagulation
which is measured with the APTT. This implies that very low factor IX
levels due to whatever cause, will be easily missed in patients on OAT.
Low factor IX levels obviously contribute to bleeding, which is the
most frequent complication of OAT.
Recently, two mutations at Ala-10 in the region of the gene coding
for the propeptide of factor IX were found which resulted in a severely
decreased factor IX level of < 1% during OAT (1,2). After discontinua-
tion of OAT the factor IX restored to normal levels, excluding
hemophilia B in these patients. The low factor IX level was believed to
contribute to the severe bleeding tendency in the four patients de-
scribed. The frequency of these mutations in the general population is not
known at this moment. If prevalent, these mutations could be a highly
relevant cause of bleeding in patients on OAT. Screening of patients
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candidate for OAT for the presence of the mutation could then result in
prevention of bleeding.
To evaluate the importance of a prolonged APTT due to low factor
IX levels in patients on OAT and the contribution of this abnormality
to the problem of bleeding, we analyzed a large number of patients
routinely treated at the Leiden Thrombosis Service. First, we measured
the APTT äs a screening lest and assessed the frequency of a dispro-
portionate Prolongation of the APTT. Subsequently, the factor IX levels
and the presence of the mutations at Ala-10 were assessed in the pa-
tients with a prolonged APTT.
To be informed about the relation of the factor IX level and the
APTT in patients with a proportionale Prolongation of the APTT we
assessed the factor IX level in 15 randomly selected patients.
Our results indicate that in the Dutch Situation it is not necessary to
screen the APTT to exclude low factor IX levels and the presence of
these factor IX mutations.
Methods
Patients routinely treated at the Leiden Thrombosis Service were evaluated
The Leiden Thrombosis Service is regionally orgamzed like all Dutch throm-
bosis Services and takes care of the control of the treatment with coumarin
derivatives for all the outpatients in the region of Leiden, The Netherlands.
The area has about 460,000 inhabitants and three hospitals. All outpatients
in the covered area are referred to our Service for anticoagulant therapy.
Annually, about 6500 patients are under treatment and 130,000 INRs are
assessed. Since 1973 all data, mcluding INR results, dosages and bleeding
complications are stored in a computerized database.
The working scheme was äs follows. At three days, after routine INR
measurement, the APTT was assessed of äs many patients äs achievable. No
selection was made, except that patients using heparin were excluded. As a
control the factor IX level was assessed in 15 patients randomly selected from
these patients. Subsequently, patients with a disproportionate Prolongation
of the APTT were selected (see below). At the next regulär visit at the Throm-
bosis Service a sample was taken from these outlier patients for assessment of
the factor IX level and the presence of the mutations.
Laboratory Methods
The INR and APTT were assessed with Recombiplastin (Ortho-Clinical
Diagnostics, Beerse, Belgium) and Cephotest (Nyegaard, Oslo, Norway)
reagent on an Electra 1000C coagulometer (MLA, Pleasantville, New York,
USA). Factor IX level was assessed on an Electra 1000C in a one stage assay
using Automated APTT (Organon Tekmka, Durhain, NC, USA) äs reagent
and commercial factor IX-deficient plasma (Organon Teknika, Durham, NC,
USA).
To detect both described changes at position -10 in the Factor IX propep-
tide (Ala^Thr and the Ala->-Val) äs well äs all other changes affecting this
amino acid, we devised a mutagenic primer that creates a Bgll (GCCN5GGC)-
site when a PCR is performed on the Ala-encoding wild-type allele. This prirner
was used äs the downstream primer m the PCR. To have a positive internal
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control for restriction enzyme activity, we changed some nucleotides in the
»pstream primer äs well, to create a Bgll site that would always be present.
Tte sequences of the primers were (altered nucleotides are shown in lower
case, and the complete or partial Bgll sites are underlined):
tipstream 5' ATGCCCTAAAGccAAATTGGCTTTCAGAT 3'
downstream 5' CCTCTTTGGCCGATTCAGAgccTTGTTG 3'.
The Ala-codon at -10 (GCC) is complementary to the last three nucleotides
(GGC) of the Bgll-site. Such a site is therefore only created when the down-
stream primer is followed by the GC of the Ala-codon encoded on the opposite
slrand.
PCR conditions were: 4 min 94° C, followed by 33 cycles of l min 94° C,
l min 60° C and l min 7 Γ C, followed by a 5 min extension time at 71° C in a
Wer consisting of 67 mM Tris-HCl (pH = 8.8), 16.6 mM ammonium
silphate, 6.7 μΜ EDTA, 6.7 mM magnesium Chloride, 10 mM 2-mercapto-
ethanol, 50 μg/ml bovine serum albumin, 10%(v/v) DMSO, 1.5 mM dNTPs
Md 20 U/ml Taq polymerase.
Äuuf/ea/ Analysis
The relation between the APTT and the INR was assessed by linear regres-
(ion analysis. Patients with disproportionate APTT Prolongation ("outliers")
*ere identified äs those with an APTT outside the upper 95% confidence limit
°f the linear regression. Standard SPSS Software was used.
Results of INR, APTT and factor IX in all patients, outliers and
«mtrols
"^  mean
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-
.
-
outliers*
n=23
3.8
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1.6
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controls
n- 15
3.1
2.3-3 9
0.5
37.3
29.4-54.6
6.0
47.6
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12.1
l ras are from the second sample. One of factor IX control patrents was found to be"""er and is included in both groups in Uns table.
Bleeding Complications
The frequency of bleeding complications was assessed äs previously de-
scnbed (3). From all patients the records were analyzed from Start of treatment
on. All bleeding complications were taken into account. Major bleeding was
defined äs intracranial bleeding, bleeding leading to admission to hospital for
treatment and muscle and joint bleeds. All other bleeding complications were
categorized äs minor.
Results
The APTT was measured in 734 patients. In one patient the APTT
was unmeasurably prolonged (> 150 s, INR 2.3), due a severe factor XII
deficiency (factor XII <1%. factor IX 36%, factor VIII 1.20 lU/ml,
factor XI 103%). The data of this patient were excluded from further
analysis.
Mean INR of the remaining 733 patients was 3.1 (ränge 1.0 to
11.1, Standard deviation 1.1). Mean APTT of the 733 patients was 38.3
(normal <32.5) s, with a Standard deviation of 7.2 and a ränge of
21.8-77.7 (see also Table 1). Linear regression analysis revealed the
following relation between INR and APTT: APTT= 23.5 + 4.8 *INR.
In Fig. l the INR and APTT results are plotted with the linear regres-
sion line and its 95% confidence limits. Twenty-five outliers were
identified. The mean APTT of the outliers was 57.6 s, with a ränge
of 43.4-77.7 s and a Standard deviation of 9.1. Of the 25 outlier
patients one died of lung cancer before follow-up was possible and
another patient had stopped anticoagulant therapy. Of the remaining
23 patients the APTT and factor IX level were (re-)assessed in a second
sample (see Table 1). The mean APTT in this second sample was
55.0 s with a Standard deviation of 6.9. The mean factor IX level was
32% with a ränge of 5-61 % and a Standard deviation of 13. In Fig. 2 the
factor IX levels are presented in relation to the APTT.
The results of the APTT and the factor IX levels in the 15 randomly
selected control patients are presented in Table l and Fig. 2. In these
patients the APTT ranged from 29.4 to 54.6 with a mean of 37.3 s and
a Standard deviation of 6.0. The factor IX level had a mean of 47.6%
with a ränge from 21 to 71 %.
For the detection of the mutation we used PCR on genomic DNA to
amplify a 176 bp fragment. The resulting fragment will contain two
365
Thromb Haemost 1999; 81: 364-6
Bgll-sites if an Ala-residue is encoded by both alleles, but only one if
another codon would be present in this position. The assay is therefore
sensitive for both the Ala -> Thr and the Ala -> Val mutation, that have
both been described äs well äs for all other possible mutations at this
position. The additional Bgll-site in the PCR-fragment serves äs a
positive control for digestion by the enzyme. All patients with out-of-
proportion APTT Prolongation turned out to carry an Ala-codon on
both alleles, excluding the presence of a mutation in this position.
Bleeding Complications
The history of bleeding complications of the 24 outlier patients
were analysed. All data available from the start of treatment on were
analysed. Total follow-up time was 109.5 years, with a ränge from
2 weeks to 141/z years, a mean of 4.2 years. A total number of 10 bleed-
ings was observed, one of which was severe (digestive tract bleeding).
So severe bleeding was found at a frequency of 0.91/100 treatment
years and minor bleeding at 8.2/100 treatment years. The patient with
the lowest factor IX level of 5% had been treated for 14^ years and
experienced only two minor conjunctival bleeds.
Discussion
We analysed 734 patients on routine treatment with oral anticoagu-
lants by screening with an APTT, followed by assessment of the factor
IX level if the APTT was disproportionately prolonged. In Fig. 2 the
relation between the factor IX level and the APTT is shown both for the
controls and for the outliers, indicating that our APTT is sensitive to
factor IX in this type of patients. We did not find any patient with a very
low factor IX level or a mutation at Ala-10 in the propeptide region of
the factor IX gene. This abnormality therefore proves not to be an
important cause of bleeding in this large group of over 700 anticoagu-
lated patients. Using a nearly identical approach Peters et al. found
one patient with a factor IX level of 7.8%, without a mutation at the
Ala-10 position (4). We found one patient with a factor IX level of 5%.
This was a 43-year-old woman who was treated with oral anticoagu-
lants for more than 14 years because of recurrent venous thrombo-
embolism. She experienced only two minor conjunctival bleeds and no
major bleeding complications. The PCR-assay we used is specific for
mutations affecting codon -10 of the factor IX gene. The presence of
another mutation affecting the factor IX level during OAT in this or
other patients therefore cannot be excluded.
We analysed a random patient sample, including patients who
recently started therapy. Selection bias caused by patients with the
mutation who stopped OAT because of bleeding therefore cannot have
majorly influenced our results. We may have missed patients if
presence of the mutation does not always result in a very low factor IX
level and a prolonged APTT. However, these patients will not have an
increased bleeding tendency and it is not clinically relevant to find
them. The method we used cannot give an exact estimate of the
frequency of the mutation in the population. However, we found 0
mutations in 734 patients and from the 95% confidence interval of
0/734 it can be deduced that less than 0.4% of the population will have
a mutation (when the mutations, if present, would always be detected
by APTT screening äs we performed). This means that screening for the
mutations of all patients who are candidates for OAT is not indicated.
Another conclusion can be drawn from our data. We analysed
bleeding complications in patients with an disproportionately
prolonged APTT. We found a frequency of major bleeding of 0.91 per
100 treatment years and a frequency of all bleeding of 8.2 per 100
treatment years. In 1988 and 1991 we found 2.7 and 2.1 major bleeds
per 100 treatment years respectively (3, 5). For all bleeding we found
16.5 and 16.6 bleeds per 100 treatment years respectively (3, 5). The
results of this investigation therefore compare very favourable with the
previous data. So, in general, assessment of APTT is not indicated to
identify patients who will experience increased bleeding on OAT.
Presence of a mutation at Ala -10 in the factor IX gene cannot be
excluded äs a rare cause of bleeding in patients on OAT. The same is
true for other abnormalities in the intrinsic pathway of blood coagula-
tion. Therefore, in patients with pronounced bleeding complications
during OAT assessment of an APTT is indicated. When the APTT is
disproportionately prolonged, factor assays have to be performed. It
may well be that the mutation, due to a higher frequency, has more
relevance in other population groups.
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